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Résumé
La surcharge génétique en fer, ou l’hémochromatose, peut être causé
par des mutations au niveau du gène HFE, hémojuveline (HJV) et
hepcidine. Des patients portant des mutations HFE ou HJV ont de
faibles niveaux d’hepcidine, indiquant que ces protéines sont impliquées
dans la régulation des niveaux basais d’hepcidine.
OBJECTIFS: Nous tentons d’élucider les conditions dans lesquelles
l’orthologue de HJV chez la souris, soit la molécule Rgmc (repulsive
guidance molecule C) pourraient influencer le métabolisme du fer. Nous
investiguerons la réponse de Rgmc aux divers modificateurs du
métabolisme du fer: niveaux de fer, anémie, hypoxie et inflammation.
RÉSULTATS: Nous avons trouvé que Rgmc, chez la souris, a un
patron d’expression similaire à celui retrouvé chez l’humain étant
exprimé dans le muscle squelettique, le coeur et les hepatocytes au
niveau du foie. Ceci indique que le contrôle de la fonction de Rgmc,
dans cet organe, est probablement médié par les hépatocytes. De plus,
nous avons trouvé que l’expression hépatique de I’ARNm de Rgmc est
régulée par l’inflammation et l’hypoxie, mais non par les niveaux de fer,
la perturbation d’HFE ou l’anémie. Finalement, nous avons étudié les
voies de régulation de Rgmc en réponse à l’inflammation et nous avons
démontré que Rgmc se retrouve dans la voie de Tlr4, ceci étant
similaire à ce qui a été trouvé pour hepcidine. Cependant, les voies de
régulation de Rgmc et hepcidine dévient et alors que li-6 régule
hepcidine, nous avons trouvé que Rgmc est régulé par Tnf-c.
CONCLUSION: La regulation de I’ARNm de Rgmc en réponse à
l’hypoxie et l’inflammation induite par le LPS pourrait contribuer au
contrôle de l’homéostasie du fer dans ces conditions. Des voies
signalitiques differéntes régulent Rgmc et hepcidine en réponse au LPS
suivant l’activation de Tlr4.
SIGNIFICATION: Ces résultats nous donne une idée considérable des
voies régulatrices ayant un impact sur les changements du métabolisme
du fer. Ces changements pourrait être pertinent pour expliquer l’origine
de plusieurs pathologies affectant l’homéostasie du fer.
Mots Clés
Inflammation, fer, LPS, TIr4,Tnf-a, Il-6, Rgmc, hepcidine, hémojuveline,
anémie des maladies chroniques, hémochromatose héréditaire,
hémochromatose juvénile.
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Abstract
Genetic iron overload. or hemochromatosis, can be caused by
mutations in HFE, hemojuvelin (HJV) and hepcidin genes. Patients with
mutations either on HFE or HJV have low hepcïdin levels, indicating that
these proteins are implicated in the regulation 0f hepcïdin basal levels.
OBJECTIVES: We intend to elucidate in which conditions the mouse
ortholog of HJV, the repulsive guidance molecule c (Rgmc) may
influence iron metabolism by investigating its response to the modifiers
of iron homeostasis: iron tevels, anemïa, hypoxia and inflammation.
RESULTS: We found that mouse Rgmc has the same pattern of
expression as found in humans, being expressed in skeletal muscle,
heart and liver, where it was expressed in hepatocytes. Additionally, we
found that hepatic Rgmc mRNA expression was regulated by systemic
inflammation and hypoxia, but flot by iron leveis, disruption of Hfe or
f32m, or anemia. Finally, we studied the Rgmc regulatory pathway in
response to inflammation and found that Rgmc is on the T1r4 pathway,
similar to what is found for hepcidin. However, Rgmc and hepcidin
regulatory pathways deviate and while Il-6 regulates hepcidin, we found
that Rgmc is reguiated by Tnf-cc.
CONCLUSIONS: Rgmc mRNA regulation in response to hypoxia and
LPS-induced inflammation may contribute to the contrai of iran
homeostasis in these conditions. Hepcidin and Rgmc are regulated by
different pathways in response to LPS after the common element of
T1r4.
SIGNIFICANCE: These findings provide important insights into the
regulatory pathways impacting iron metabolism change, which may be
relevant to disease settings affecting iron homeostasis.
Keywords
Inflammation, iran, LPS, T1r4, Tnf-Œ, Il-6, Rgmc, hepcidin, hemojuvelin,
anemia of chronic disease, hereditary hemochromatosis, juvenile
hemochromatosis
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Abbrevïations
ACD — Anemia of chronic Uisease
ATP — Adenosine triphosphate
DCYTB — Duodenal cytochrome b
DM1 — Divalent metal transporter
[PC — Erythropoietin
FBS — Fetal bovine secum
FP1 — Ferroportïn 1
FTH — Ferritin heavy polypeptide
FTL — Ferritin light polypeptide
GPI — Glycosyl phosphatidylinositol
Hb — Hemoglobin
HCP — Heme carrier protein
HCT — Hematocrit
HH — Hereditary hemochromatosis
HIF — Hypoxia inducible factor
HJV — Hemojuvelin
HO — Heme oxygenase
IL — Interleukin
IRE — Iron responsive element
IRP — Iron regulatory protein
LPS — Lipopolysaccharide
MCV — Mean corpuscular volume
MHC — Major histocompatibility complex
mRNA — Messenger ribonucleic acid
NF-iB — Nuclear factor kappa B
NK — Natural killer
NO — Nitric oxide
XNIBI — Non-transferrin bound iron
OMIM — Online endelian inheritance in man
PCR — Polymerase chain reaction
PHL — Phlebotomy
PHZ — Phenylhydrazine
PS — Penicillin-Streptavidin
qRT-PCR — Quantitative real-time PCR
RBC — Red blood celi
RGM — Repu lsive guidance molecule
RT-PCR — Reverse transcription-polymerase chai n reaction
Tf
— Transferrin
TfR — Transferrin receptor
TLR — Toli-like receptor
TNF — Tumor necrosis factor
Note: Gene and protein symbols were written in accordance to
international nomenclature conventions (1-3). Briefly, human gene and
protein symbols are written in capitals and mouse equivalents are
written with the first letter capital and remaining letters in underscore;
genes are written in italic while proteins are normal case (e.g. RGMa
refers to a human protein whereas Rgma refers to a mouse gene).
Some exceptions exist (e.g. DMT1, which is aiways written in capitals).
INTRODUCTION
Chemïcal propedïes and biological functïons of
Iran
Iron is involved in a wide array of metabolic functions in ail organisms
and is thus essentiai for normai oeil growth and proliferation. Ihis is
namely due to its capacity to form a variety cf coordination complexes
with organic ligands in a dynamic and flexible mode which, along with its
ability to switch between the ferrous (Fe2) and ferric (Fe3) states (of
+772 mV at neutral pH (4)), allowed for the evolution of several,
functionally diverse, iron proteins.
Many cf the iron proteins accommodate iron in the form cf heme and are
generally designated as hemoproteins. The most abundant cf the
hemoproteins are the oxygen binding proteins hemogiobin and
myoglobin, present in great quantities in red biood ceils (RBC5) and
muscle, respectively (5). Other hemoproteins include cytochromes and
enzymes, such as oxygenases, peroxidases, or nitric oxide synthases
(4).
2Most non-heme iron proteins contain iron-sulfur clusters (6) and play
diverse roles ranging from electron transfer, transcriptional regulation
and structural stabilization to catalysis (4).
The iron feature of which the above proteins make use, i.e. the capacity
of iron to easily participate in oxidation-reduction reactions in conditions
compatible with the constrains of the cellular environment, also account
for the spontaneous reaction by which iron catalyses the formation of
hydroxyl radicals (0H) from hydrogen peroxide (F1202), a process
known as Fenton chemistry (7) (figure J). 0H readily reacts with DNA,
proteins and lipids inducing mutations and cellular stress (8).
The reactive essential for the Fenton reaction, H202, originates as a
byproduct of enzymatic reactions or from the detoxification cf products
such as superoxide (02) by supetoxide dismutases and is usually
detoxified by catalase or glutathione peroxidase to H20 (9). H202 reacts
with Fe2, which is weakly chelated by a variety cf ligands such as
citrate, phosphate, carbohydrates, carboxylates, nucleotides,
nucleosides, polypeptides and phospholipids (10, 11). The impact of iron
toxicity through Fenton chemistry is evidenced by the reduction of
cellular damage by the use cf iron chelators which prevents iron from
reacting with H202 (8).
3Detoxïflcatïon Fenton-derived toxicïty
o.2
Superoxide
Dismutase
Fe2 Lipid,
Enzymatic H2o2 —• 0H , DNA and
Actïvity Protein
Catalasel Oxidation
Glutathione
peroxîdase
H20
Fe2 + H202 Ite3’ + 0H + 0H
(Equation for the Fenton reaction)
Figure I — Iron catalyzed generation of the hydroxyl radical via the
Fenton reaction. H202 arising from the detoxification of superoxide by
superoxide dismutase or from other enzymatic activities may be
detoxified by catalase or glutathione peroxidase to H20 or participate in
the genetation of hydroxyl radicals, a reaction catalyzed by iron as may
be seen in the equation for the Fenton reaction.
4The duality cf iron as an essentia) micronutrient and as a cellular toxic
imposed the evolutïon cf highiy regulated systems for the celluiar iron
uptake and storage in a non-toxic form, which wiII be discussed in the
next section.
5Cellular ïron balance
Iron transport, uptake and storage
The main source of iron for mammalian celis is from transferrin (Tf), a 79
kD protein divided into two evolutionary related lobes, the N-lobe (336
amino acids) and C-lobe (343 amino acids), which are linked by a short
spacer sequence (12). Each lobe contains two domains comprising a
series cf Œ-helices, which overlay a central 13-sheet backbone (12). The
domains interact to form a deep, hydrophilic iron-binding site which has
a ‘closed’ form with one Fe3 atom stabilized at neutral pH and an ‘open’
form when the pH is reduced to around 5.5 (5, 12).
Tf is synthesized mainly by hepatocytes (13) and is found in various
body fluids including plasma, bile, amniotic, cerebrospinal, lymph and
breast milk (14). It has an half-hfe cf eight days and plasma
concentration is relatively stable from birth, ranging from 2 to 3 gIL in
humans (12).
From the 2-3gIL of Tf, that which has bound-iron (holo)-Tf has a higher
affinity to the Tf receptors (TfRs) than non-iron-biding (apo)-Tf (12).
There are two TfRs. TfRI is expressed in RBCs, erythroid ceils,
hepatocytes, monocytes and the blood-brain barrier (12). TfR2 is
expressed as two transcripts (Œ-TfR2 and 3-TfR2), with Œ-TfR2
6expressed predominantly on liver ceils and 3-TfR2 expressed at 10w
levels on a variety cf ceil types (15).
Figure 2 schematizes the process of Tf-bound iron uptake. Upon
ïnteracti on cf Tf wïth TfR the Tf-TfR complex s internalized and
adenosine triphosphate- (ATP) dependent proton pumps acidify the
endosomes te pH 5.5, inducing 1f to release the bound iron (5). The
recently identified ferrireductase Steap3 then reduces Fe3 te Fe2 (16),
which is transported into the cytoplasm by the divalent metal transporter
1 (DM11) (17). The apo-Tf-TfR complex remains stable until the
endosome is recycled and transported back to the membrane, where
apo-Tf liberates from the TfR returning to the extraceliular environment
(18-20).
it should be noted that not ail iron enters the celis through the Tf/TfR
system. A non-Tf bound iron (NTBI) uptake system also exists. NTBI is
normally found in 10w levels in heaithy individuals. However, in
pathological conditions such as primary or secondary iran overload,
NTBI levels are augmented.
To maintain cellular iron reserves in a non-toxic form, NIBI and TfR
acquired iron is loaded into ferritin, an iron storage protein.
7hoto-Tf
apo-Tf
Figure 2 — TIITfR-mediated iron uptake. Holo-Transfemn (Tf) interacts
with Tf receptor, inducing its endocytosis. A proton pump acidifies the
endocytic vesicle ta pH under 5.5, which induces the release of Fe3
from Tf. Fe3 is reduced by the ferrireductase Steap3 to Fe2 and is
transported ta the cytoplasm by the divalent metal transporter I (DM11).
Iran may then be incorporated into ferritin for storage. The 1f receptor is
then recycled back to the membrane and apo-Tf s released ta the
extracellular space.
TfR
Fe2e
Steap3
Ferritin
8Ferritin is a sphecical sheli composed of 24 units 0f the ferritin light (FTL)
or heavy (FTH) polypeptides capable of storing around 4500 atoms of
iron in a ferrihydrite core (21). The polypeptides are very similar in
structure. However, they have been shown to have different
physiological properties. FTH is capable of iron binding, and has been
associated with ferroxidase activity, whereas the iron binding site in FIL
has been replaced by a sait bridge (22). FIL is more stable than FTH
and has been shown to promote the ferrihydrite nucleation (23). It is not
clear yet how ferritin regulates iron incorporation and release or how
each polypeptide participates in this regulation. Generally, ferritins with
high FIL percentage are associated with stable ferrihydrite containment
and are thus found in tissues associated with iron storage, such as the
liver. FIH-rich ferritins are believed to be implicated in iron detoxification
through ferrous iron oxidation (24) and are found in energy demanding
tissues, such as the heart and brain.
Ceuar iron balance is therefore maintained by equilibrium between iron
uptake and storage. Although several factors may be implicated in this
balance, cellular iron levels are central to the balance modulating the
activity of iron regulatory proteins (IRPs).
9Iron regulatory proteïns and elements
Iron regulatory proteins (IRPs) are messenger ribonuceic acid (mRNA)
binding proteins with high affinity for hairpin secondary structures known
as “iron responsive elements’ (IREs) (25). IREs are present on the
untranslated regions cf several genes coding for proteins implicated in
iran metabolism, including the 1fR and ferritin polypeptides (25). The
nucleotidic sequence of the IREs is phylogenetically conserved in
vertebrates and some insects and bacteria. A typical IRE is composed
cf around 30 nucleotides and form a 5’-CAGUGN-3’ Ioop (the underlined
C and G interact by hydrogen bonding) and a stem with moderate
stability, interrupted by an unpaired C residue (25) (figure 3).
Two different IRPs bind IREs, IRP1 and IRP2 (25). Although structurally
similar, the two IRPs are very differently regulated. IRP1 contains an
iron-sulfur 4Fe-4S cluster that in 10w LI P levels loses one iron. This
Ieads to a change in the conformation cf the protein into the apo-IRPI
IRE-binding form, which has a 3Fe-4S cluster (26). IRP2, on the other
hand, is regulated by iron-induced degradation and the amount cf bound
IRP2 ta IREs directly correlates with the amount cf protein (27). In
summary, IREs wiII predominantly have IRPs bound (bath IRP1 and
IRP2) when cellular iron levels are Iow.
10
The IREIIRP system therefore allows for an intracellular iron-sensing
mechanism, relaying its signaling by the control of translation and
mRNA degradation. The presence cf IREs on the 5’UTR inhibits
translation when lRPs are bound and IREs on the 3UTR augment
mRNA levels by blocking degradation by RNases.
G3 G3
A2U4 A2U4 Loop
N6 N6
N-N N-N
N-N N-N Upperstem
N-N N-N
N-N N-N
NN N-N
c - c Bulge
G C N-N
U N-N
N-N N-N
N-N N-N Lowerstem
N-N N-N
N-N N-N
5-N-N-3 5-N-N-3’
Consensus IRE with Consensus IRE with
‘entin-like” bulge single C bulge
Figure 3 — Consensus IRE motif. Two forms cf iron responsive
elements (IREs) are shown. On the left is represented an IRE similar to
the ferritin IRE, with a UGC on the 5’ end 0f the hairpin, with a single C
on the 3’ end cf the bulge. On the right we see an IRE with a bulge with
a single C at 5’ end cf the hairpin, as found on 1fR IREs.
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A classical example of gene control by IRPs pertaïns to the iron storage
and uptake equilibrium. FTL and FTH have a 5’ IRE and TfR1 has five 3’
IREs (25). When LIP levels are 10w TfR1 mRNA wilI be protected from
degradation and translation of the ferritin polypeptides will be inhibited.
Conversely, high LIP levels wiIl release IRPs from the IREs, TfR1 mRNA
will be degraded and ferritin translation will be initiated.
As a result, high cellular iron levels elevate ferritin levels, providing a
safe storage place for iron and diminish 1fR levels, reducing ton uptake.
The inverse will be found in conditions of low LIP levels (see figure 4).
The IRE/IRP system allows for the control cf intracellular iron levels.
However, in mammals, cellular iron levels depend not only on the
regulation cf iron uptake at the ceil membrane, but aIse on the
availability cf iron in the body. Mechanisms for systemic iron regulation
are therefore requited.
12
RNAse RNAse
+
TfRI 5Lr -jSL’iLiLî_IAAAA 3’ AAAA 3’ t TfRI
Translation Translation
initiation complex initiation complex
t ferritin 5’___L_tzEEEEEJ_AAAA 3’ 5’_—_I?-__[EEEEEE}—AAAA 3’ ferritin
Fïgure 4 — Responses to ïron supply mediated by IRE-IRP
interactions. Iran regulatory proteins (IRPs) bind to iron responsive
elements (IREs) in 10w iran conditions and leave IREs free in the
presence of iran. IRPs bound ta IREs on the 3’ UTR (as taund in the Tf
receptor 1 (TfR1) mRNA transcript), wiII block mRNA degradation by
RNases. IRPs bound ta 5’ IREs (as found in ferritin) inhibit protein
synthesis by perturbing the binding cf the translation initiation complex.
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The systemic ïron recydllng
In mammals the major amount of iron is heme-bound, cf which iron
found in hemoglobin is the most common. It is therefore flot surprising
that most cf the iron in humans is found in erythrocytes (5). From the 3-5
g of iron present in the human body. approximately 1.8 g is found in
hemoglobin in the erythrocytes, i.e. roughly 40% of the total body iron.
Erythrocytes typically have a life span of 120 days (28). To compensate
for senescent erythrocytes. over 200 billion new erythrocytes are
produced daily (29), making erythropoiesis the major iron-demanding
process in the body.
To provide for erythropoiesis demand,
phagocyte senescent RBCs and heme
iron from heme. The free iron may
macrophages onto the bloodstream
Subsequentty the bone marrow uptakes
daily requirements (figure 5).
iron is recycled. Macrophage
oxygenase (HO) releases the
then be exported from the
to be bound to If (29).
the Tf-bound iron to fulfill its
Proportionally, only a very slight amount of iron is taken up by the
rema ining cells for physiological use, of which muscle ceNs are the
major iron containing ceNs, in the form of myoglobin (17). The sole
exception is that 0f the liver. Hepatocytes have very high amounts cf
ferritin-associated iron and the liver is therefore regarded as an iron
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storage compartment, supptying iran in times cf dietary iron deflciency
(17).
Since most cf the body iran is recycled, the requirement of dietary iran is
suaIty due ta iran tasses. These include iran lost through desquamation
cf gastrointestinal ceils, bleeding and other mmcc tosses (17).
In summary, celis may be regarded as acceptors or donors. Virtually alt
the celis in the body are iron acceptors, with erythropoietic precursor
cells and hepatocytes as the main iron-demanding celis. The celi types
that are considered ta be iron danors are 1) macrophages, after
scavenging cf iran from hemoglobin; 2) hepatocytes, in conditions of
iran sparseness; and 3) enterocytes, respansible far absarbing Iran in
the duadenum (see figure 5 for a schematic representation).
The recycling 0f iron implies that dietary iran requirements are anly
needed ta compensate for iran lasses and ta support body growth.
Given the nanexistence cf a cantralled iran excretion system, bady iran
levels must be regulated at the level af iran absorption.
15
Figure 5 — Systemic ïron re-cycling. Iran lasses have ta be
compensated by iron absorption at the duodenum. Absorbed iran s
released into the bloodstream where it is bound to Transferrin (Tf).
Erythroid precursors uptake the Tf-iran ta produce RBCs. Senescent
RBCs are phagosized by the reticuloendothelial macrophages and the
Iran is recycled back into the bloodstream. Hepatocytes store excess
iran and supply it when body iran levels are reduced.
____
____
___
t Duodenum 1
[ Iron Loss 1 Li-2 mg!J
Ljz2 mgIda’J I,..
tOther ceNs 1 Fe-Tf
L -400mg_J —3mg
lit
f Liver 7
Li000mg]
[Bonemarroj I
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Iron absorption
As discussed, normally only s small amount of iron is absorbed daily
from the diet. A tight regulation af this absorption is required since
excessive iron absorption can ultimately lead to iron overload.
Iron is absorbed mainly at the level of the duodenum, where it arrives in
two forms from the diet: heme and non-heme iron. Non-heme iron is
present as iron hydroxides and saits and in iron-containing proteins such
as ferritin. 0f the twa forms, heme Iran is the more bioavailable, with
levels 0f absorption from a meal containing heme of about 25%.
Heme-bound iron is uptaken by the recently identified heme carrier
protein 1 (HCP1) expressed in the apical region of epithelial cells in the
duodenum (30), and is not affected by other dietary components, with
the possible exception of calcium (31).
Non-heme iron is much less bioavailable, with absorption rates from the
diet 0f 1-15% (32). The absorption efficiency varies with other
components of the diet than may enhance or inhibit it. Examples of
promoters of iron absorption are ascorbic acid and citric acid (33).
Among inhibitors are components such as phytic aclU, polyphenols (e.g.
tannins) and calcium (32).
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Promoters of iran absorption mainly have the effect of converting fercic
iran ta fertous iran. In addition, Fe3 can be reduced by the
ferrireductase duodenal cytochrame b (Dcytb), present at the brush
border membrane of duodenal enterocytes, enriching the amount of
Tuminal Fe2 (34). Fe2 is then uptaken by enterocytes by DMT1 directly
from the lumen, which efficiently transports Fe2, but flot Fe3(35).
Inhibitors of iran absorption typically work by chelating iran or compete
with iran for DM11 transport (e.g. calcium) (32, 35).
In the enterocyte iran may either be stored in ferritin or is exported by
ferroportin 1 (Fpl) ta the bloodstream ta complete the process af iran
absorption. Fpl is most likely the only iran exporter in mammals, since
Epi knockout mice are embryonic lethal (36). After transport of the Fe2
across the enterocytic membrane by Fpl, the ferroxidase hephaestin
oxidizes iran to Fe3, which can then bind ta Tf (37).
The scheme in figure 6 illustrates the mechanisms involved in iran
absorption.
The observation that in mice, Epi disruptian in the duadenum abrogates
iron export from the enterocytes suggests that iron absorption is mainly
controlled by Fpl regulation (36). Recently it has been shown that Fpl
can be regulated bath at transcriptional and post-translational levels by
a newly identified hormone called hepcidin (38).
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Figure 6 — Intestinal iron absorption. Iron in the diet may be oxidized
(Fe3), teduced (Fe2) or bound to heme. Fe3 must be reduced by the
duodenal cytochrome b (Dcytb) to be transported across the plasma
membrane by the divalent metal transporter I (DMTI) into the
enterocyte. Heme is uptaken by a specific carrier, the heme carrier
proteïn 1 (HCPJ) and its iron is scavenged by heme oxygenase (HO).
Iron is then incorporated into ferritin for storage (the stored iron is
eventually Iost by desquamation of the epithelial celis) or exported out of
the enterocyte by ferroportin I (Fpl), oxidized by hephaestin (Hp) and
bound to Tf for transport in the blood.
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Hepcïdïn
Hepcidin was recentiy discovered independentiy by three groups as a
mouse peptide expressed in response to iran leveis and
iipopolysaccharide (LPS) (39) and as a hurnan antimicrobial peptide of
the 3-defensin famiiy found in urine (40) and biood — where it was
designated LEAP-1 (liver expressed antirnictobiai peptide) (34). In ail
reports the authors show that the peptide is highiy expressed in the liver.
Mice deficient for hepcidin are iran overloaded (41) while converseiy,
transgenic mice overexpressing hepcidin are severeiy anemic (42)
further stressing the important raie of hepcidin in iron rnetaboiism.
A ciue onto the mechanism of action for hepcidin cornes from the
observation that hepcidin interacts with the iron exporter Fpl inducing its
internaiization and degradation (38), and reducing Fpl rnRNA
expression (43). Lower protein Fpl levels would ultimately iead to
reduced arnounts of iran being exported from the enterocytes into the
circulation, therefore reducing iran absorption.
Coiiectiveiy, these observations strongly support the notion that hepcidin
is a ngative regulator of iran absorption. In fact, hepcidin mRNA ieveis
can be reguiated by iron, anernia, inflammation and hypoxia (44), four
pathways reguiating iron homeostasis.
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Regulation ofiron homeostasïs
Iron absorption is adjusted depending on the amount of stored iron, the
erythropoietic demand, oxygen levels and inflammation (43). It was
initiaiiy hypothesized that severai different regulators were implicated in
the regulation of iron absorption in those conditions. The identification 0f
hepcidin as a negative regulator of iron absorption, and the observation
that its expression is reguiated in ail the above conditions (44) suggests
that hepcidin is the common regulator in ail conditions. Figure 7
schematizes the hypothesized pathways regulating hepcidin in response
to iron leveis, erythropoietic demand, oxygen leveis, and immune
system activation.
Regulation of iron homeostasis by Iran stores
It s Iogical that the iron stores, or iran levels, should be one of the
factors regulating iron absorption, and therefore hepcidin, in order to
avoid iron overioad or deficiency.
The iiver serves as an iron storage organ by uptaking excess iron and
later distributing it when body iron ieveis are iow. Due to this function of
iron storing and since the liver is the main site of hepcidin production,
body iron stores sensing is believed ta take place in this organ.
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Serum ferritin, If and soluble 1fR have ail been proposed as candidate
signal ing molecules for the regulation of hepcidin in response to iran
levels (45-47), howevet which moiecuie, if flot ail mentioned, and the
pathways leading to hepcidin regulation have stili ta be elucidated.
Regutatïon of iron homeostasîs by erythropoietic
demand
Erythropoietin (EPO), which regulates RBC production is a glycoprotein
mainly produced in the kidneys, but also synthesized in the liver and to a
lesser extent in the spleen, lung, testis and brain (48). EPO inhibits the
apoptosis of erythrocytic progenitors in the bone marrow (49), allowing
for an increased number of matured hematopoietic ceils in the presence
of high levels of EPO.
Tissue hypoxia is the main stimulus of EPO production and its levels
exponentially increase with decreasing blood hemoglobin (Hb)
concentration (50). EPO gene expression is not only stimulated when
the 02 capacity of the biood decreases (usually correlating with the Hb
concentration), but aiso when the arterial p02 decreases (as found in
high altitudes) (51).
There are severai reguiatory DNA sequences in the neighborhood of the
EPO gene, but the key element is located within the so-called hypoxia
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response element, which is bound by the hypoxia-inducible transcription
factors (HIES). HIEs are dimers composed of one cx and one 13 subunit,
There are at least three subtypes of the HIF-cx subunit (1, 2cx and 3u).
HIF-lcx/f3 is generally considered the primary mediator of hypoxia
induced gene expression (48). HIF-lcx is regulated by oxygen
dependent degradation. Only in hypoxia is HIF-lcx enabled ta enter the
nucleus and ta heterodimerize with HIE-113, inducing HIF-1-regulated
genes, such as EPO.
In summary, erythropoietic demand, regulated by EPO, arises in two
main situations: decreased Hb levels as found in anemia, or decreased
P02 levels, as found in hypoxia due ta environmental 10w oxygen levels,
such as found in high altitudes. The first is described below and the
second is described in following section.
Anemia
Anemia is defined as a deficiency in hemoglobin and/or RBC levels
linked ta poor tissue oxygenation. Patients commonly report a feeling 0f
weakness and fatigue and in cases of severe anemia, shortness 0f
breath. Etiologically anemia is caused by 1) decreased RBC production;
2) increased RBC destruction and/or 3) blood Ioss.
Decreased RBC production may arise, for instance, due ta Iow body iron
levels. The condition termed iron deficiency anemia arises when
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erythroid progenitors have insufficient hemoglobin synthesïs due to the
ow iran availability. RBCs produced in conditions of iron deficiency
typically have a smaller volume, as measured by the mean corpuscular
volume (MCV), and is therefore morphologically classified as a
microcytic anemia (52).
Another fotm of anemia that is associated with impaired iron distribution
ta erythroid precursors is the anemia of chronic disease (ACD).
However, in contrast to iran deficiency anemia, patients with ACD do not
have decreased body iron levels. In addition, in contrast to iron
deficiency anemia, the pathogenesis of ACD is not only associated with
impaired iton distribution to erythroid precursors, but also with increased
RBC destruction and impaïred EPO production.
ACD may arise in individuals with chronic infections and cancer. The
underiying pathogenesis induce secretion of high levels of pro
inflammatory cytokines (53), which contribute to the development of the
anemia by inhibiting EPO production (54), increasing the rate of RBC
phagocytosis by macrophages (55) and inhibiting the release of iron
from hepatocytes and macrophages through the upregulation cf
hepcidin (56). The hepcidin-mediated decrease in iron release to the
serum is believed to be the main causative factor of the underlying
chronic hypoferremia in ACD, which leads to deficient iron delivery to
the erythroid precursors.
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Regulation of iron homeostasïs by Hypoxïa
Subjecting mice to hypoxîa by housing in a hypobaric chamber resuits in
hepcidin downregulation. as found in anemia and consistent with the
iron demand for erythropoiesis (44), and hepatocytes cultured in vitro
subjected to hypoxia decrease hepcidin expression (44).
However, other stimuli seem to be implicated in the increased iran
absorption in response to hypoxia. An increase in erythropoietic demand
induced by EPO is known to decrease hepcidin levels (57), but seems to
produce littie or no increase in iron absorption (56, 59). The increase in
iron absorption observed in hypoxia, afthough it is likely regulated by
hepcidin to a certain level, seems to require other factors, such as H-6,
since administration of Il-6 antibody to hypoxic mice halves the hypoxic
response of iron absorption (60). These additional factors support for an
hypoxia pathway separate from the erythropoietic pathway (61).
Reg ulation of iron homeostasis by the immune system
Iran is important in several aspects of immunosurveillance because of
its growth-promoting role for immune celis and its interference with celi
mediated immune effector pathways and cytokine activities (62-64).
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Iron homeostasis and the adaptïve immune system
It has been demonstrated that iron deficiency as weB as won overload
can exert subtie effects on immune status by altering the proliferation
and activation of T-, B- or natural killer (NK)-cells (53). Conversely,
indirect evidence (Hfe, a nonclassical major histocompatibility complex
class I that has been implicated in iron sensing is directly recognized by
cytolytic CD8÷ T cells (65); higher iron levels are found in Hfe-/
recombinase-activating gene (Rag)1 -J- double knockouts than in either
cf the single knockouts (66); and 10w CD8+ peripheral T celI numbers
increases the tisk of severe hemochromatosis (67)) suggests that the
immune system could participate in iron homeostasis.
Iron homeostasis and the innate immune system
Pathogens require iron for growth and replication. Since the amount cf
iran that is not protein-bound in serum and tissues is diminute (68),
bacteria have evolved several mechanisms for seizure and uptake 0f
protein-bound iron, ranging from production of iron sequestering
molecules (siderophores), to importers of Tf and lactoferrin (69).
Conversely, the host has devefoped mechanisms to hinder iron
availability for bacteria. One of these mechanisms is the reduction cf
seric iron levels (hypoferremia) (70).
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Hepcidin expression is increased in response to inflammation by Il-6 and
Il-113 (71, 72) and, since it is has been shown that hepcidin inhibits Fpl
(38), the sole iron exporter in mammals, and it is capable of inducing
hypoferremia, it has been hypothesized that the development of
hypoferremia is dependent on hepcidin upregulation (73).
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I
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Figure 7 — Pathways for hepcidin regulation. Signaling of ïron stores
level Ieads f0 the regulation of hepcidin levels. The erythropoietic and
hypoxic pathways are intertwined since Iow red blood ceils (RBCs) or
10w hemoglobin levels (Hb) in anemia induce tissue hypoxia, activating
HIEs and augmenting EPO production. II-6 and II-1f3 are produced in
response to inflammation and these regulate hepcidin. Dashed unes —
hypothetical pathways.
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Hereditary Hemochromatosîs
Hereditary hemochromatosis (HH) is an iron overloading disease
caused by mutations in Hfe (type I), hepcidin or hemojuvelin (type II),
transferrin receptor 2 (type III) and ferroportin I (type IV). In this study
we will give emphasis to type I and II HH.
Heredftary hemochromatosis - Type I
Type I hemochromatosis is an autosomal recessive disorder 0f iron
metabolism (onhine mendelian inheritance in man (OMIM) 235200).
Patients absorb excessive amounts cf dietary iron, which leads to ton
overload. This excess iton accumulates mainly in the hiver, pancreas
and heart.
If left untreated, patients may develop iron-induced complications such
as cirrhosis, diabetes or cardiomyopathy typicalhy occurring around the
5th decade of hife.
Treatment usuahly consists of bleeding (phlebotomy) and patients rarely
devehop significant chinical symptomatology, having a hife expectancy
similar to heahthy individuals (74).
Mutations on HFE, a nonclassical major histocompatibihity complex class
1 (MHC-I) mohecuhe is the causative factor of type I HH.
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The HFE ancestral peptide bindïng groove is toc narrow to aflow classic
antigen presentation (75) and the function of HFE has net yet been
established. However, the observation that HH type I patients and mice
deficient in Hfe have 10w basaI hepcidin levels (76) indicates that Hfe
plays a role in the setting of adequate basal hepcidin expression levels,
The low basal hepcidin levels are consistent with the excessive iron
absorption found in the patients, which leads to tissue iron overload.
Two main mechanisms cf action cf HFE that may impact on hepcidin
expression levels have been proposed: the inhibition by HFE 0f the
TfffR iron import system, and the free HFE signaling to extra- or intra
cellular partners.
tnhibïtïon of TfITfR import
HFE interacts with 1fR (75) and competes with differric 1f for TfR
binding (figure SA), suggesting that some of the effects of HFE on iron
homeostasis resuit from the inhibition cf Tf-mediated iron import by HFE
(77, 78) (79) (figure 8B).
Free HFE sïgnaling
Accumulating evidence suggests that the effect of HFE on iron
homeostasis may net be solely due to an inhibition of the If-mediated
iran import. Evidence supporting this hypothesis includes the facts that
1) Tf is capable of effectively compete with HFE for TfR binding even at
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concentrations cf Tf wel) be)ow those found in the blood (80), and
therefore HFE woutd have very Iimited capacity to block Tf-mediated
iron uptake; 2) the W81A HFE mutant, which has 5000-fold Iower affinity
for TfR1 binding than wildtype HFE (81), regulates Tf-mediated iron
uptake to the same extent as wildtype HFE in vitro (82) and; 3) HFE
iowers intracellular iron levels even in celis that Iack TfR1, providing
evidence for another mechanism of intraceflular iron level regulation,
probabty through control cf NTBI iron uptake (80) (figure 8C).
In addition, the recent observation that T ceils directly tecognize HFE
(83) indicates that HFE may have a role as a signaling molecule for the
adaptive immune system, which has the capacity to regulate iron
homeostasis through the release of cytokines (figure 8C)
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Figure 8 — Mechanistic models for HFE function. (A) HFE competes
with Tf for transferrin receptor (TfR) binding. It is believed that this
competition resuits in (B) an inhibition cf Tf-mediated iron uptake by
HFE or (C), the release cf HFE from 1fR, allowing I celi recognition of
HFE or intracellular signaling leading to the regulation of NTBI iron
uptake or iron export.
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Hereditary hemochromatosïs - Type II
Type Il HH is characterized by an earlier onset than type I HH and was
therefore also designated Juvenile Hemochromatosis (JH). It is
associated with a high lethality rate caused mainly by cardiomyopathy
by the 3rd decade of Hfe (84). JH has been found ta have twa causative
factors: loss of function mutations in hepcidin fOMIM 606464) (85) and
hemojuvelin (HJV) (OMIM 608374) (86).
lnterestingly, JH patients with mutations in HJV have very 10w hepcidin
levels (87). The low hepcidin levels in classical HH and JH provide for a
common mechanism cf pathology and implicate HFE and HJV in
hepcidin regulatian, however, the pathway leading ta this regulation stiil
has ta be discerned.
HJV is a soluble or glycosyl phasphatidylinositol (GPI)-anchored protein
cf unknown function that has an Arg-Gly-Asp (RGD) domain and a
partial von Willebrand factor type D damain and shows high similarity
with human repulsive guidance molecules (RGM) a and b, two proteins
invclved in axanal guidance (88). Due to this high similarity, the mouse
ortholog of HJV is tecmed Rgmc f see figure 9 for an alignment cf HJV
and Rgmc proteins). However. Rgmc. in contrast to Rgma and Rgmb, s
not expressed in the nervaus system and does nat seem to be
implicated in axonal guidance (89).
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HJV has been shown to be expressed in the heart, skeletal muscle,
liver, and fetal liver and absent from brain, colon, thymus, spleen,
kidney, duodenum, placenta, lung, lymph. lymphocytes and bone
marrow (86).
It is flot clear how HJV functions. As mentioned before, loss cf function
mutations leads to very 10w hepcidin levels, which seems to be the
causative factor for the iron loading, but it is not known how HJV is
implicated in hepcidin regulation.
This thesis centers on the control of Rgmc expression in mouse models
cf altered iron homeostasis to elucidate in which conditions Rgmc may
influence iron metabolism.
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Mdv MGEPGQSPSPRSSRGSPPTLSTLTLLLLLCGMAIiSQCKILRCNAEYVSSTLSLRGGGSSGIRGGIGGRGGGVG
75
mRgmc SGGLCRALRSYALCTRRTARTCRGPLAPMSAVHGIEDLMIQHNCSRQGPTAPPPARGPALPGAGP P
DPCDY 143
MJV SGGLCRALRSYALRRTARTCRGDLAPHSAVHGIEDLM1QflNC5RQGPTAF?PPRGPALPGAGS PD
PCDY 150
mRginc EARFSRLHGRAPGPLHCASPGDPRVRSPHNQFMTCRVQGAWPLLDNDFLPVQATSSPVSEGANAT
RKTTIIFK 219
HJV EGRFSRLMGRPPGFLMCA5FGDPHVR5PHMHFHTCRVQGAWPLLDNDFLFVQATSSPMAGANAT RKLT
IIFK 225
***t**t***************** * ****
********************* *
mRgmc NNQECIOQKVYQAEVDNLPWEDGSINGGDRPGGS5LSIQTAGSMVEIRAAYIGTTTIIRQTAGQLSFSIRV
293
Mdv NNQECIDQKVYQAMVDNLPVAFEDGSINGGDRPGGSSLSIQTAtGNHVBIQAAYIGflhIIRQTAGQLSESIKV
300
***** •**************t****************.***
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**t**
mRginc AEDV FSAEQDLQLCVGGCPPSQRLSRSEPNRRGAIAIDTARRLCKEGLPVEOAYFQSCVPO SGDPNFW
369
MJV AFIN FSAEQDLQLCVGGCPPSQRLSRSERNRRGAITIDTARRLCKEGLPVEDAYFHSCVFD ISG
DPNFTV 375
mRgtc
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.LVPLLSALFVLWLCFS 420
Mdv AAQAALBDAR2FLPDLRKLMLFPSDAGUPLSS LAPLLSGLFVLWLCIQ- 426
Figure 9 — Hemojuvelin and the mouse ortholog Rgmc protein
alignment. ClustaIX was used for the alignment. Low scoring
aminoacids are marked with black background.
Objectives and specïfic aims
Objective:
We intend to elucidate in which conditions HJV/Rgmc may influence iron
metabolism by investigating its pattetn of expression in response to the
modifiers cf iron homeostasis: iron levels, anemia, hypoxia and
inflammation.
Aïm I — Characterization of Rgmc tissue and ceil
mRNA expression by quantitative real-time
polymerase chain reaction.
In humans, the Rgmc ortholog, H]V, has been shown to be expressed
in the heart, skeletal muscle, liver, and fetal liver and absent from brain,
colon, thymus, spleen, kidney, duodenum, placenta, lung, lymph,
lymphocytes and bone marrow (86). To elucidate whether Rgmc has a
similar pattern of expression in mice, we assessed Rgmc mRNA
expression by quantitative real-time polymerase chain reaction (qRT
PCR) in heart, skeletal muscle, liver, brain, thymus, spleen, kidney,
dLloder.u m, lung and bone marrow. We also investigated whether Rgmc
is expressed n hepatocytes or liver mononuclear cells.
36
Aim 2 — Profiling cf Rgmc liver mRNA expression in
mouse models of altered iron metabolism.
We decided to study Rgmc mRNA expression at the level of the liver,
given the importance of this organ on iran homeostasis and as the main
site of synthesis of hepcidin. Expression levels were measured by qRT
PCR using mause models for the four modifiers of iran homeostasis:
Iran levels, anemia, hypoxia and inflammation. To study Rgmc mRNA
expression in response to iron levels, we used mouse models of
nutritional iron loading and deficiency. Additionally we used the genetic
iron overloaded mouse models of HH: Hfe and fi2m knockout mice. For
the analysis of the effect of erythropoiesis on iron homeostasis, we used
the models cf phenylhydrazine f PHZ)-induced hemolytic anemia and
phlebotomy-derived anemia. Ta study the effect of increased
erythropoiesis without anemia, as found in hypoxia, we subjected mice
to 10% oxygen levels for 1, 3 and 5 days. Finally, we used LPS to
modify iran homeastasis in response ta inflammation.
Aim 3 — Study Rgmc regulatory pathway downstream
ofLPS.
We faund that Rgmc is markedly downtegulated in inflammation. We
therefore perfarmed a time-caurse analysis af Rgmc regulatian and
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studied the regulatory pathway in response to LPS treatment. We
studied the capacity cf Toli-like receptor (TIr)4 deficient mice and Hfe
and fi2m knockout mice to regulate Rgmc mRNA expression in
response LPS. In addition, we investigated the regulatïon cf Rgmc in
response to the infiammatory cytokines II-6 and tumor necrosis factor
(Tnf-)Œ in vivo and in vitro.
Materïals and Methods
Animais
Ail animal manipulations were carried out under Canadian Council on
Animal Care regulations and approved by the Animal Care Committee of
the Centre Hospitalier de l’Universite de Montreal (CHUM). Hfe mice
have been previously described (90). fl2m’, II-6’, C3H/HeJ and
C3H/OuJ were purchased from Jackson Laboratories f Ben Harbor,
Maine, USA). Except for the C3H mouse strains, ail animais were
backcrossed over 10 generations with C57BI/6. Animais were tended for
in light- and temperature-controlled environment and were given free
access to tap water and food — the commercial diet TD 2018 (Harian
Teklad, Madison, Wisconsin, USA) except otherwise stated.
Animal Treatments
For the inflammatory stimulus, 10 weeks-old mice were injected intra
peritoneally with 5 mg/Kg E. cou LPS serotype 055:65 (Sigma-Aldrich,
St. Louis, Missouri, USA) or 1 pg recombinant mouse Il-6 (3 hours
before sacrifice) or Tnf-Œ (6 hours before sacrifice) (Cederlane
Laboratories Ltd, Hornby, Ontario).
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b analyze iron homeostasis in response to iron Ieves, B weeks-old
mice were subjected to an iron-deficiency diet (TD 80396; Harlan
Teklad) or the standard commercia’ diet supplemented with 2.5% (wtlwt)
carbonyl iron (Sigma-Aldrich) for two weeks.
To induce anemia through ph)ebotomy (PHL), 0.25 ml of btood was
extracted by retro-orbital puncture from anesthetized mice. The
procedure was repeated 24 hours later, and the animaIs were sacrifïced
16 hours after the last PHL.
Hemolytic anemia was produced by intra peritoneal administration of 40
mglkg body weight of PHZ (Sigma-Aldrich), once daily for 4 days and
the mice were sacrificed at day 5.
Hypoxia was elicited by housing of mice in a closed chamber with
controlled injection of N2 and 02 and with outward ventilation for removal
of excess CC2 and humidity. Mice were subjected to a 02 graduaI
reduction 02 from 20.8% to 10% 02 over 6 hours and were
subsequently housed at 10% 02 for 1, 3 or 5 days.
Prïmary hepatocytes isolation and cultures
Mice were anesthetized and the livers were perfused with HEPES buffer
(Sigma-Aldrich) at 37 oc for 4 minutes at 10 milmin followed by a
40
perfusion with HEPES buffer supplemented with 0,14 UIml Collagenase
D (Roche, Sainte-Foy, Quebec) at 37 oc for 7-8 minutes at 10 mi/min.
Dissociated celis were isolated by gentie rubbing of the liver with a
rubber policeman. Hepatocytes were peileted at 100 x g for 4 min at 4°C
and washed twice with Wiiliams E incompiete medium (Invitrogen). Ihe
washed hepatocytes were then resuspended in 25 ml of Williams
incomplete media (Invitrogen) and layered onto a 50-ml conical tube
containing 20 mi of Percoil (Sigma-Aldrich) (1 part lOx Hank’s balanced
sait solution and 9 parts Percoll). The hepatocytes were mixed with
Percoli by inverting five times and peileted by centrifugation at 300 x g
for 10 min at4°C.
Finally, hepatocytes were washed once and were plated at 2.5 x i04 per
cm2 onto type I collagen in Williams E medium with 10% fetal bovine
serum (FBS) and 1% penicillin and streptavidin (PS). Two hours after
plating, medium was changed and replaced with fresh medium. 20
hours after plating ceNs were treated with 20 ng/ml Il-6 or Tnf-Œ or 100
ng/ml LPS for 24 hours.
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Uver mononuclear ceils (LMCs) isolation
LMCs wete separated by centrifugation using the lympholyte density
medium (Cederlane, Hornby, ON, Canada), following the supptiers’
instructions.
RNA quantification
Tissue samples were stored in RNALater (Ambion, Austin, Texas, USA)
following the suppliers’ instructions. Total RNA was subsequently
extracted with TRIZOL reagent (Invitrogen). Reverse transcription (RT)
was performed with the Omniscript RI Kit (Qiagen, Mississauga,
Ontario) using random hexamers (Invitrogen) and RNase inhibitor
(Invitrogen) in the concentrations suggested by the supplier.
mRNA levels of Rgmc, /3-actin and hepcidin were measured by real-time
PCR in a Rotor Gene 3000 Real lime DNA Detection System (Montrea!
Biotech inc, Kirkland, Quebec) with the Quantilect SYBR+Green I PCR
kit (Qiagen). Ail primers were designed using the Primer3 algorithm (91)
so that they would flank at least one intron. The following primers were
used in this study: /3-actin 5’-TGHACCAACTGGGACGACA-3’ and 5’-
GGTGHGAAGGTCICAAA-3’; Rgmc 5’-
AAITICACACATGCCGIGTC-3’ and TCAAAGGCTGCAGGAAGATT
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3’; hepcidin 5’-AGAGCTGCAGCCTHGCAC-3’ and 5-
GAAGATGCAGATGGGGAAGT-3’.
Relative quantitation was performed using standard curves constructed
from serial dilutions of PCR products and were attributed arbitrary
concentrations. Alt standard curves generated were found to have
excellent PCR amplification efficiency (90%-96%; 100% indicates that
after each cycle the amount of temptate is doubled). as determined by
their slopes. mRNA expression for each gene was determined by direct
comparison with the standard curve of the specific target generated in
each PCR run. Expression levels of the genes of interest were
normalized to the housekeeping gene fi-actin.
Serum ïron and transferrïn saturation
measurements
Serum iron and total iron binding capacity (TIBC), and transferrin
saturation were assessed by colorimetric assay with the Kodak
Ektachem DT6O system (Johnson & Johnson, Ortho Clinical
Diagnostics, Mississauga, Ontario).
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Measurements of tissue iron concentration
Tissue samples were dried by incubating at 106 oc overnight and
weighed ta determine the tissue dry weight. Tissues wete then ashed by
incubating at 500 oc for 17h and iran was dissolved in 6N HCI. Iran
levels were quantified by atomic absorption spectroscopy at the
Geochemistry laboratory of the École Polytechnique de l’Université de
Montréal.
Statïstïcal analysis
Student t test (unpaired, 2-tailed) was used for comparison between 2
groups. Multiple comparisons were statistically evaluated by one-way
analysis of variance (ANOVA) followed by the Benferroni test.
Resuits
Aim I - Tissue Expression
Rgmc tissue and celi expression
The understanding cf the role cf Rgmc encompasses the study cf its
tissue expression. We investigated the pattern of mRNA expression 0f
Rgmc by qRT-PCR and found it expressed in the liver, heart and
skeletal muscle (figure I OA) and absent from spleen, duodenum, kidney,
lung, thymus, brain and bone marrow. This is in accordance to what has
been previously described for mouse (89) and the human ortholog HJV
(86). Therefore, as in human HJV mRNA expression, mouse Rgmc
mRNA expression is found in the organs that are most affected in JH.
Taking into account the importance of the liver in iron homeostasis, we
concentrated our studies in this organ and evaluated mRNA production
in hepatocytes and mononuclear ceils, separated using differential
centrifugation in order to understand in which ceN population further in
vitro experimentation on Rgmc regulation should be performed. We
found Rgmc mRNA expression only in the hepatocyte fraction (figure
lOB) indicating that Rgmc signaling is being mediated by the
hepatocytes.
45
A
ci)
cD
h.
B
0.4
0.3 T
Rgtnc
fi-actin
4, -,
Figure 10 — Murïne Rgmc tissue and celi expression. Rgmc mRNA
expression was assessed using qRT-PCR (bargraphs) and classical RI
PCR (gel images) in several tissues (A), and in two liver ceil fractions
obtained by differential centrifugation, separating the hepatocytes from
the remaining liver mononuclear celis (LMC) (B). Resuits are presented
as means ± SEM (n=2-3).
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Aim 2 — Rgmc response to modïfiers of iron
homeostasïs
Iron Levels
To assess how iron levels regulate Rgmc we next quantified Rgmc
mRNA levels in 10 weeks alU C5ZBI/6 mice subjected to standard, low,
or high iran diets fot two weeks.
We observed 2% dectease in Mean Corpuscular Volume (MCV) in the
mice fed the low iron diet (table I), indicative that cell division in the bone
marrow continues for longer than usual, resulting in smaller ceils,
However the mice did flot developed anemia, as seen by analyzing
RBC, Hb and HCT values. Mice fed with the high iran diet had slightly
increased RBCs (7%), Hb (6%), HCT (9%) and MCV (4%).
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Table I — Hematological indices of mice treated with a low, standard
and high iron containing diets. Red blood ceils (RBC), hemoglobin
(Hb), hematocrit (HCT) and mean corpuscular volume (MCV) 0f 10
weeks alU mice treated for twa weeks with a diet deficient in iran (-Fe), a
standard laboratory diet (Std) or a diet with additional 2.5% w/w carbonyl
iron (+Fe). Resuits are presented as means ± SD (n=6 mice per group).
Statistical analysis was pertormed by one way ANOVA followed by the
Benferroni test. *p.<oos p<0,01, ***p<O 001 (compared to Std).
RBC Hb HCT MCV
Group (1 06/ml) fgIdl) (¾) (fL)
-Fe 9.5 ± 0.4 13.1 ± 0.5 42.4 ± 1.8 45 ± 0.8**
Std 9.2 ± 0.2 13.2 ± 0.2 42.6 ± 0.8 46 ± 0.4
+Fe 9.8±0.2* 14.0±0.3 46.5±0.9 48±0.5**
Mice feU with the 10w iran diet decreased body stores, as may be
observed in the decrease of liver iran levels (43%) in comparison with
mice fed a standard iron diet (table li), indicating that mice did indeed
reduce the liver iran stores. However, this reduction in the lïver iran
stores did flot influence circulating iran levels, since SI and TS
parameters do flot change, probably due ta the release of liver stored
iran into the circulation. Mice feU with the high iran diet became iran
overloaded as seen by the over two-fold increase in circulating iron
levels as well as liver iran levels, compared ta contraIs (table Il).
Rgmc mRNA levels, however, did flot differ among the mice subjected
to the different diets (figure 1 lA), indicating that Rgmc regulation at the
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mRNA level is not implicated in the control of iron homeostasis in
response to iron stores.
Table Il — lron measurements ïn mice treated with a low, standard
and high iron containing diets. Serum iron (SI), transferrin saturation
(TS) and liver iton levels were quantified in 10 weeks old mice treated
for two weeks with a diet deficient in iron (-Fe), a standard Iaboratory
diet (StU) or a diet with additional 2.5% w/w carbonyl iron (+Fe). Resuits
are presented as means ± SD (n=6 mice per group). Statistical analysis
was performed by one way ANOVA foliowed by the Benferroni test.
***p<Q 001 (compared to Std).
SI 15 Liver Iron
Group (M) (%) (fig iron/g dry weight)
-Fe 21±3 40± 2 124± 17***
Std 19±2 46± 5 221 ± 20
+Fe 394*** 109±15** 569±177***
Hereditary hemochromatosis
Based on the observation that mice lacking a functional Hfe protein have
lower than expected basal hepcidin levels (92), hepcidin has been
proposed to be in the Hfe pathway. In continuation with the hypothesis
that hepcidin is a downstream target cf Rgmc, we investigated whether
Rgmc levels in the primarily iron-overloaded fi2m and Hfe knockout
mice may explain the Iow basal hepcidin levels.
fi2m and Hfe’ mice have around 2-fold more liver and circulating iron
than controls (table III), similar to mice fed with a high iron diet
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Liver Iran
(ig iron/g dry weight)
308 ± 40
726 + 1 48***
738 ± 227
compared with contraIs (table II). In spite of the high iron levels, these
mouse models of HH displayed Rgmc levels akin to wildtype mice
(figure 11 B), suggesting that abnormal Rgmc regulation in this mice is
flot the causative factor for their Iow basal hepcidin levels in these
strains.
Table III — Iron measurements in mice with genetic iron
overloading. Serum iran (SI), transferrin saturation (TS) and Hver Iran
levels were quantifled in 10 weeks old wildtype (Wt), f32m’ or Hfe’
mice. Results are presented as means ± SD (n=6 mice per group).
Statistical analysis was performed by one way ANOVA followed by the
Benferroni test. *p<O,O01 (compared to Wt).
SI TS
Group (1iM) (%)
Wt 20±3 41±9
Hfe 45±3 96± 8
fi2m 34±6* 94±21***
50
A
0.4
c.D
.0
I zr
=
-Fe StU
B
0.4
0.3
0.2
0.1
0.0
+Fe
Figure 1f — Hepatîc Rgmc mRNA expression in response to iron
levels and in HH mouse models. Rgmc mRNA expression quantified
by qRT-PCR and normalized to /3-actin in (A) 10 weeks old mice treated
for two weeks with a diet deficient in iron ), a standard Iaboratory diet
(LI) or a diet wîth additional 2.5% w/w carbonyl iron (D); (B) 10 weeks
old wildtype (, Hfe’ (E) or fi2m’ (D) mice. Resufts are presented as
means ± SEM (n=6 per group). Statistical analysis was performed by
one way ANOVA.
Wt Hf&’ /f2m
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Hypoxia
To investigate whether Rgmc mRNA levels are regulated by hypoxia, we
subjected 10 weeks-old mice to 10% oxygen levels for 1, 3 or 5 days.
Mice subjected to hypoxia elevated RBCs by 15% by day 1 ta a
maximum of 25% increase by day 5 (figure 12A). HCT values were also
elevated by day I to 15% and the maximum increase cf 27% was
attained by day 5 (figure 12B). This increase of RBCs and HCT values
in response to hypoxia are in accordance to what has previousiy been
described (93) and indicate that the mice increased the erythropoiesis in
response to the hypoxic stimulus.
TS increased 44% at day I and decreased to 40% of basal levels by
day 3, returning to levels similar ta normoxic contrais by day 5 (figure
12D). SI behaved similarly. However, in contrast to TS, the slight
increase by day 1 was not statistically different, there was a marked
decrease to 51 % of normoxic controls by day 3. At day 5 SI leveis were
similar to normoxic mice (figure 1 2C).
The increase cf TS at day 1 suggests a mobilization cf iran from storage
to meet the erythropoietic demand and the TS and SI decrease by day 3
may reflect a reduction cf iron in the stores. By day 5 TS and SI start to
stabilize and approach the levels found in normoxic control.
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Rgmc levels were found upregulated 2-fold by day 1, after which it
decreases ta 146% cf basal levels by day 3 and to levels similar ta
normoxic controis by day 5 (figure 13) suggesting that Rgmc may play a
role in the changes observed in iran metabolism during acute hypoxia.
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Figure 12 — Hematological îndices and iron measurements in mice
subjected to hypoxïa. 10 weeks old mice were subjected to 10%
oxygen levels (hypoxia) for 1, 3 or 5 days. Controls remained in
normoxic conditions (21% oxygen). Blood was extracted as described in
materials and methods and the hematological indices of red blood ceNs
(A) and hematocrit (B) were measured. Serum iron (C), and transferrin
saturation (D) were also quantified. Results are presented as means ±
SEM (n=5 per group). Statistical analysis was performed by one way
ANOVA foNowed by the Benferroni test. *p<005 **p<OO1 ***p<0 001
(compared to normoxic group).
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Fïgure 13 — Hepatic Rgmc mRNA expression in response to
hypoxia. Rgmc mRNA expression quantified by qRT-PCR and
normalized to 16-actin in 10 weeks old mice subjected to 10% oxygen
levels (hypoxia) for 1, 3 or 5 days. Controls remained in normoxic
conditions (21% oxygen). Resufts are presented as means ± SEM (n=5
per group). Statistical analysis was performed by one way ANOVA
followed by the Benferroni test. *p<005 **p<OO1 (compared to
normoxic group).
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Anemia
To assess how Rgmc may be important for iton homeostasis in anemia,
we subjected 10 weeks-old C5ZBI/6 mice ta phlebotomy- and hemolytic
derived anemias. In the phlebotomy-treated mice, successive bleedings
lead ta a 3-fold reductïon of RBC numbers, Hb levels and HCT (table
IV), whereas no significant changes were found at the levels of SI or TS
(table V). In hemolytic anemia, the lysis of RBC led to s 3-fold lower
RBC count and HCT and a 26% reduction on Hb (table IV). However, in
contrast ta what was found in the phlebotomy model, a drastic increase
in SI (3-fold) and TS (2-fold) is also found, probably due ta the release of
the iran from the lysed RBCs into the bloodstream (table V). This data
indicates that we were abte to induce anemia in bath of the mouse
models.
Rgmc mRNA expression was found not ta change in either of the twa
models (figure 14), suggesting that, in contrast to what was found in the
model for hypoxia, changes in Rgmc mRNA expression are not
implicated in the regulation of iran metabolism in response ta anemia.
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Table IV — Hematological indices in PHL and PHZ treated mïce. Red
blood ceils (RBC), hemoglobin f Hb), hematocrit f HCT) and mean
corpuscular volume (MCV) 0f 10 weeks alU mice phlebotomized fPHL)
or with phenylhydrazine(PHZ)-induced anemia, as described in the
material and methods section. Resuits are presented as means ± SD.
Statistical analysis was performed by one way ANOVA followed by the
Benferroni test. *p<0,001 (compared ta contrai).
RBC Hb HCT MCV
Group N f 106/mI) (gIdi) f %) (fL)
ContraI 6 9.3±0.3 13.7±0.5 42.3±1.8 46±0.8
PHL 5 3.2±0.3 5.1 ±0.6* 14.3±1.3*** 45±08
PHZ 6 2.9±0.2* 10.2±0.9*** 13.0±1.7 45±2.9
Table V — Iron measurements in mice PHL and PHZ treated mice.
Serum iron (SI) and transferrin saturation (TS) in 10 weeks old mice
phlebotomized f PHL) or with phenylhydrazine(PHZ)-induced anemia, as
described in the methods section. Results are presented as means ±
SD. Statistical analysis was performed by one way ANOVA followed by
the Benferroni test. ***p<0 001 (compared to control).
Si 15
Group N (pM) f %)
Control 6 25 ± 3 58 ± 7
PHL 5 24±7 56±16
PHZ 6 71 ±10*** 120±19***
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Figure 14 — Hepatic Rgmc mRNA expression in response to
anemia. Rgmc mRNA expression quantified by qRT-PCR and
normahzed to /3-actin in 10 weeks old non-anemic control mice $), with
phlebotomy-derived anemia (PHL) (E) or with phenylhydrazine-induced
anemia (PHZ) (D). Resuits are presented as means ± SEM. Statistical
analysis was performed by one way ANOVA.
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Inflammation
In inflammation hypoferremia takes place, characterized by a decrease
in SI and 15, as seen in table VI (2-folU reduction for both parameters).
Hypoferremia implies a change in iran homeostasis. To elucidate
whether Rgmc regulation may be implicated in iron homeostasis in
inflammation we treated mice with lipopolysaccharide (LPS) for 6 hours
and quantified hepcidin and Rgmc mRNA levels. We found that mice
treated with LPS downregulate Rgmc mRNA expression 6h after
injection ta 2% cf basal levels (figure 15), indicating that cegulation of
Rgmc mRNA levels may be implicated in the changes observed in iran
homeostasis in response to inflammation.
Table VI — Iron measurements in response to systemic
inflammation. 10 weeks old mice were treated with LPS and sacrificed
after 6 hours. Serum iron (SI) and transferrin saturation (15) was
measured. Results are presented as means ± SD. Statistical analysis
was performed using the Student t test. ***p<Q 001
SI TS
Group (p.M) (%)
CTRL 17±1 30±8
LPS 7±1 16±2***
Figure 15 — Hepatic Rgmc mRNA expression in response to
systemic inflammation. Rgmc mRNA expression quantified by qRT
PCR and normalized to /3-actin in 10 weeks oid contrai mice and in mïce
treated with LPS for 6 hours. Resuits are presented as means ± SEM
(n=6). Statisticai analysis was performed using the Student t test.
***p<O 001
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Aim 3- Inflammatory Pathway
lime Course
The observation that Rgmc is regulated by inflammation at 6h leU us to
further study the kinetic response subjecting 10 weeks-old C57Bl/6 mice
to LPS treatment for 6h, 17h, 24h and 48h both in the liver and heart.
Mice injected with LPS Ueveloped hypoferremia as seen by a decrease
of SI and TS to 30% of basal levels by 6h without significant changes
after 17h or 24h. After 48h both parameters rise to 140% (SI) and 160%
(TS) cf basal levels (figure 16A and B).
We found that after the downregulation observed at 6h, Rgmc mRNA
levels consistently rose to 21% cf basal levels by 17h after treatment
and reached 40% cf basal levels by 48h after the treatment, still
significantly Iower than control (figure 16C). Similarly, cardiac Rgmc had
an approximate 50% reduction in mRNA levels that persisted for 48 h
(figure 16D).
0.4
0.3
0.2
0.0
80
60
40
20
0.4
0.3
0.2
< 0.1
61
Fîgure 16 — Iron parameters and gene expression in response to
systemic inflammation over time. Mice were treated with LPS and
sacrificed 6, 17, 24 and 48 houts after injection (n=4). Serum iron (SI)
(A) and transferrin saturation (IS) (B) wete measured, as weII as
hepatic (C) and cardiac (D) Rgmc mRNA Ievels expression, quantified
by qRT-PCR and normalized to /3-actin. Resuits are presented as
means ± SEM (N=4 per group). Statistical analysis was performed by
one way ANOVA foUowed by the Benferroni test. *p<oo5: **p<OO1;
***p<O 001 (compared to controls).
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Rgmc repressïon by LPS is independent of Hfe
Next, to assess whether changes in Rgmc mRNA expression are
appropriately elicited in Hfe-deficient mice, we measured Rgmc mRNA
expression in Hfe and fl2m mice after LPS administration. As shown
in figure 17, Hfe-deficient mice responded like wildtype mice, by
dramatically down-regulating their hepatic Rgmc mRNA expression.
This demonstrates that the ability to down-regulate Rgmc during the
acute phase response remains intact in the absence of functional Hfe.
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Figure 17 — Hepatic Rgmc mRNA expression in response to
systemic inflammation in hereditary hemochromatosîs mouse
models. Rgmc mRNA expression quantified by qRT-PCR and
normalized to /i-actin in 10 weeks old wlldtype (Wt), Hfe’ and /32m’
control mice and in mice treated with LPS for 6 hours. Resuits are
presented as means ± SEM (n=6). Statistical analysis was performed
using the Student t test. **p<OOl
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Rgmc regulation ïs T1r4-dependent
Pathogen-assocïated molecular patterns (PAMP), including LPS are
rcognized by TLRs which, upon activation, leaU to the production of
pro-inflammatory cytokines. LPS is a PAMP that is recognized by T1r4
(94). To investigate whether T1r4 is on the regulatory pathway 0f Rgmc
in response to LPS, we injected witdtype and T1r4-deficient mice with
LPS. These mouse strains have more iron, and develop a smaller
hypoferremia (reducing SI by 34% and TS by 43%
- table VII),
compared with C5ZBI/6 mice. Rgmc mRNA expression levels, however,
differed dramatically between both strains after treatment (figure 19).
Wildtype mice downregulated Rgmc levels to I % cf the basal levels,
whereas the 11r4-deficient mouse strain did flot significantly respond te
the treatment, placing Rgmc regulation in response to inflammation on
the T1r4 pathway.
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Figure 18 — Hepatïc Rgmc regulation is T1r4-dependent. Rgmc
mRNA expression quantified by qRT-PCR in wildtype or T1r4-deficient
(TIr4d) mice treated with LPS for 6 hours. Resuits are presented as
means ± SEM (n=5). Statistical analysis was per[ormed by one way
ANOVA followed by the Benferroni test. ***p<O 001 (compared to
control).
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Table VII — Iron measurements in response to systemic
inflammation in wildtype and T1r4-deficient mice. 10 weeks alU
wildtype or TIr4-deficient (TIr4d) mice were treated with LPS and
sacrificed after 6 hours. Serum iran (SI) and transferrin saturation fIS)
was measured. Resuits are presented as means ± SD. Statistical
analysis was performed using the Student t test. *p<OOS (compared to
respective controi).
SI TS
Group N (rM) (%)
Wt ContraI 4 35 ± 4 61 ± 14
WtLPS 4 23±7* 35±10*
TIr4d ControI 5 35 ± 5 70 ± 10
TIr4d LPS 5 20 ± 8* 39 ± 18*
Tnf-a downregulates Rgmc
Ihe 11r4 signaling pathway ieads ta activation of the transcription factor
Nf-KB, which initiates the transcription of pro-inflammatory cytokine
genes such as Tnf-Œ and Ii-6. To ascertain whether those cytokines are
imphcated in Rgmc regulation, we treated C57B116 mice with
recombinant mouse Il-6 or Tnf-a for 3 or 6 h or with LPS for 6 h.
Tflf-Œ and Ii-6 were bath able to reduce Rgmc mRNA, aibeit iess than
LPS treatment. In fact, Inf-Œ induced a 72% decrease at 3h and 45% at
6 h, whiie li-6 caused only a 40% deciine at 3 h (figure 19A).
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To investigate whether Tnf-Œ regulates Rgmc by acting direcfiy on
hepatocytes, we ïsolated primary hepatocytes and incubated them for
24 h with Tnf-Œ, Il-6 and LPS and quantifled Rgmc mRNA expression
levels. Tnf-Œ, but flot Il-6 or LPS, elicited a significant downregulation of
Rgmc mRNA Jevels (38%) (figure 19B). SimiJar to what has previously
described (72), we found that II-6 upregulates hepcidin by 38% in mouse
primary hepatocytes, whereas LPS induces a 29% dectease (figure
190). Finally, hepcidin mRNA levels did flot significantly change n
response to Tnf-Œ.
This data indicates that Tnf-Œ is capable of directly regulating Rgmc in
hepatocytes.
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Figure 19 — Rgmc mRNA expression is decreased by Tflf-Œ, but flot
II-6. Rgmc mRNA expression quantified by qRT-PCR and normalized to
/3-actin in control (CtrI), Tnf-Œ, II-6 and LPS-treated mice (A). Rgmc (B)
and hepcidin (C) mRNA expression quantified by qRT-PCR and
normalized to fi-actin in primary hepatocytes treated with Tnf-Œ or II-6 (4
experiments) or LPS (3 experiments) for 24 hours. Resuits are
presented as means ± SEM. Statistical analysis was performed by one
way ANOVA followed by the Benferroni test. *p<o,o5; **p<ool;
***p<O 001 (compared to control).
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II-6 ïs not required for Rgmc down-regulation in
response to LPS
To further exclude the possible requirement for Il-6 in Rgmc down
regulation during inflammation, we tested the response to LPS of Il-6
knockout mice.
As seen in table VIII both mouse strains significantly decreased SI and
TS levels in response to the LPS treatment.
There were no differences in basal Rgmc levels among the mouse
sttains, and both were able to regulate Rgmc levels in response to LPS
(figure 20). Wildtype and II-6 knockout mice reduced Rgmc mRNA
expression to 8% and 11 % of basal levels, respectively.
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Figure 20 — II-6’ mice downregulate Rgmc mRNA in response to
LPS. Rgmc mRNA expression quantified by qRT-PCR and normalized
to /3-actin in control () and mice treated with LPS for 6 hours (D) in
wildtype (Wt) and II-6. Resuits are presented as means ± SEM (n=4).
Statistica analysis was performed by one way ANOVA followed by the
Benferroni test. * p<0,05 (Compared to respective control)
CtrI LPS Ctrl LPS
Wt II-6’
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Table VIII — Iron measurements in mïce treated with LPS or a high
iron containing diet low. Serum iran (SI), transferrin saturation (TS)
and liver iran levels were quantified in 10 weeks alU wildtype (Wt), or II
6’ mice treated with LPS for 6 hours. Resuits are presented as means ±
SD. Statistical anatysis was performed by one way ANOVA followed by
the Benferroni test. *p<QQ5; **p<001; ***p<0 001 (compared to
respective contrai).
SI IS
Group Treatment N (.tM) (%)
Ctri 4 16±1 33±2
t LPS 4 8±2* 16±2**
II 6 Ctri 4 16 ± 1 38 ± 3
- LPS 4 8±1*** 22±4*
Discussion
in this study we wished to elucidate where, when and how Rgmc is
regulated in mice. We thetefore investigated the pattern cf tissue
expression, the regulation in response to modifiers 0f itOfl metabolism
and the regulatory pathway in response to systemic inflammation.
Tissue expression
We have found that Rgmc is exptessed in skeletal muscle, heart and
liver — where Rgmc is expressed only at the levels of hepatocytes —
indicating that human (86) and mice (this study) have the same pattern
0f expression.
Simiiarly, others conclude that Rgmc is absent from macrophages and
other liver mononuclear oeil and that it is exclusively present in
periportal hepatocytes (95). in that study the authors knocked out the
Rgmc gene and inserted the lactosidase reporter gene under the RgmC
promoter, allowing for the histological observation of the sites of Rgmc
expression.
Rgmc/HJV is present in the oeil membrane, intracellular compartments
and the supernatant of cuitured ceNs (96) and serum (97), suggesting
that Rgmc may function both as a GPI anchored protein and as a
diffused molecule. Supporting this hypothesis is the fact that soluble
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HJV is capable of regulating iron homeostasis in primary human
hepatocytes (97).
The possibility that Rgmc may function as a diffused molecule is further
supported by the identification cf the Rgmc receptor: neogenin (96).
Neogenin is also a receptor for Rgma and Rgmb, mediating signaling
regarding axonal guidance. In vitro transfection in human HEK293 celis
with neogenin and HJV increased iron uptake and ferritin teveis, in
comparison with control ceNs or ceils transfected with oniy neogenin or
HJV, demonstrating that neogenin also has a rote in iron homeostasis.
The presence of Rgmc transcript onty at the leve) of periportal
hepatocytes therefore does flot necessatily imply that it mediates the
signaling only in these celis. It can be released from the periportal zone
and, through neogenin, it may mediate signating te the rest of the liver.
in addition, the expression cf Rgmc in tissues other than the liver, along
with the observation that it is found in the serum as a diffused molecule
(97), raises the question cf how Rgmc may be impticated in local iron
metaboiism in the heart and muscle and whether its activity 15 merely
local or also systemic.
Rgmc may be capable cf providing signais to any celi expressing
neogenin. Neogenin expression has been atmcst exclusively studied in
embryonic development in relation to signal mediation for Rgma and
73
Rgmb. Now it is evident that neogenin tissue expression and regulation
may have an important raie in iron metaboiism in the aduit, making it an
interesting moiecule to study in this fieid.
Rgmc regulatïon ïn response to modifiers of iron
homeostasis
Rgmc regulation in response to Iron stores
Human sufferers become iran Ioaded either through the diet (e.g. HH
patients) or through repeated biood transfusions (e.g. tteated
thaiassemics) (98).
We have anaiyzed Rgmc regulation in response ta iton stores by
varying the amount of iton in the diet and have flot found any variations
in Rgmc mRNA leveis between mice fed with 10w, standard or high iran
diets, modeis of dietary iron loading.
in conttast to our data, it has recentiy been reported by that repeated
daily iron-dextran injection for 5 days in mice increases Rgmc
expression levels (99). A substantial difference between that mode!
(designated parenterai iran loading, s mode! of iran loading such as
found in treated thalassemics) and ours is that in our mode!
macrophages are flot iron Ioaded, in contrast ta what happens in the
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iron-dextran model (99, 100). Iron loading at the level 0f the
macrophages may affect cytoki ne production (101) and ROS levels and
induce the differences found between the models.
Despite the fact that Rgmc mRNA levels are flot regulated by iron,
recent evidence emerging from Rgmc knockout mouse studïes indicate
that Rgmc plays an essential role in the iron-sensing pathway at the
systemic level (95). Injection of iron-dextran in Rgmc knockout mice
does not resuit in the upregutation of hepcidin, in contrast to what is
observed in the wildtype animais, indicating that Rgmc is implicated in
the mediation 0f ItOfl sensing signaling.
in addition, in both HEK293 and Hep3B ceil unes engineered to express
HJV, soluble HJV release was progressively inhibited by increasing ton
concentrations (97) indicating that iron-mediated release of HJV may be
one mechanism by which Rgmc signais iron levels to downstream
targets.
Together, this data suggests that the iron signaling mediated by Rgmc is
performed by regulation of Rgmc secretion, without the adjustment cf
expression levels. This implies that Rgmc is constantly being produced
and secreted, and that the Rgmc transcript levels found in the cetis are
enough to produce the required amounts of protein for secretion,
independently of the level of iran stores.
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Rgmc levels ïn Hereditary hemochromatosîs
Liver iron levels in mice with Uietary iron overload reach levels similar to
those found in the genetically iron overloaded mice fl2m’ and Hfe’.
These mouse models have Rgmc levels similar to those found in Wt
mice, indicating that perturbation of Rgmc mRNA regulation does flot
participate on the pathogenesis of classical hereditary
hemochromatosis. The low basal hepcidin levels found in these mice
are therefore flot explained by 10w Rgmc transcript levels.
It is possible that Hfe abrogation alters Rgmc function at the protein
level. However, if Hfe would alter Rgmc signaling, for instance, by
participating on the regulation of Rgmc secretion, fl2m and Hfe’ mice
would be expected flot to properly regulate hepcidin in response to iron
Jevels. Nevertheless, these mice have been found to have an adequate
hepcidin response in response to low or high iron diet treatments as
shown by us (102) and others (103).
Rgmc regulation in response to anemia and hypoxia
We have found that acute hypoxia, but not anemia, regulates Rgmc
mRNA expression. Similarly, it has been recently reported that Rgm
mRNA expression is flot altered in response to phlebotomy-induced
anemia (104) or EPO in vivo (57).
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It is believed that hepcidin levels directly correlate with Rgmc levels, as
it has been observed in vitro (96). However, the upregulation of Rgmc
mRNA levels in response to hypoxia does flot induce an upregulation in
hepcidin transcription (data flot shown).
Hepcidin has recently been shown to be regulated by erythropoiesis
based on the observations that hepcidin downregulation in anemia is
inhibited by blockage of erythropoiesis by irradiation or posttransfusion
polycythemia, even in the presence cf exogeneous EPO (105). The fact
that Rgmc mRNA is flot regulated by erythropoiesis (as seen in the
models for anemia and exogenous EPO administration), in contrast ta
what was shown for hepcidin (105), suggests that hepcidin and Rgmc
are regulated by different pathways in hypoxia.
Anemia is known to induce tissue hypoxia. Therefore, the absence cf
Rgmc mRNA regulation in response to anemia raises the question of
which factors are differentially regulated in hypoxia induced by 10w
oxygen levels and anemia-induced hypoxia.
EPO and HIF-1 are activated in both modes and are therefore unlikely
to be the ones implicated in Rgmc mRNA regulation. Additional studies
wiII be required to identify the Rgmc regulatory pathway in response ta
hypoxia.
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Rgmc regulatïon in response to inflammatïon
As others (57), we have found that Rgmc is downregulated 6 hours after
LPS-induced inflammation. In addition, we have found that this
downregulation persists for at least 48h after the stimulus.
Hepcidin seems to be regulated by two independent pathways: one in
response to inflammation, through Il-6 and Il-1 3 (71, 72), and another, in
response to iron levels, through Rgmc and neogenin (95, 96). Others
have suggested that Rgmc downregulation in response to LPS serves ta
switch off hepcidin regulation by iran levels eliminating inter[erence from
this pathway and allowing hepcidin to be regulated only by cytokines
(95).
We propose that the low Rgmc levels, sustained for at least 48 hauts
after LPS challenge may desensitize the iron signaling pathway,
considering that Rgmc has been shown ta be implicated in iron sensing
(95). This may facilitate the iran release from macrophages and
hepatocytes allowing the replenishment of setum iran levels and the
recovery from the hypoferremia.
The response ta LPS seems to be tissue-specific, as Rgmc down
regulation is flot seen in the skeletal muscle of mice treated with LPS
(95), in contrast ta what is observed in the liver. We further show that
the down-regulation of Rgmc mRNA expression also occurs in the heart,
78
whete hepcidin is as weII expressed (100). This indicates that Rgmc
regulation by LPS may have an important role in cardiac iran
homeostasis in cardiomyopathy. This could be pertinent, sinGe
cardiomyopathy is considerably more frequent in JH than in HH.
Rgmc regulatory pathway in inflammation
The molecular signaling mechanism for Rgmc regulation by LPS seems
ta involve T1r4, as Rgmc down-modulation was abrogated in bath the
liver and heart of 11r4-deflcient mice treated with LPS. However, T1r4-
deficient mice and mice lacking downstream elements, such as H-6
knockout mice are stili able to respond with hypoferremia, whieh
indicates that iron metabolism changes elicited by LPS may occur
through bath T1r4- and non-T1r4-dependent mechanisms.
Activation of the T1r4 pathways uftimately resufts in the production of
pro-inflammatory cytokines, including Il-6 and Tnf-a, which are known to
directly influence iran metabolism. We found that mice injected with Tnf
Œ or Il-6 downregulated Rgmc mRNA levels. However, of these
cytokines, only Tnf-a down-regulated Rgmc mRNA levels in vitro. Pro
inflammatory cytokines are known ta induce each other’s expression
(106), which may explain why II-6 had a modest repressive effect on
Rgmc mRNA expression in vivo.
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The fact that II-6’ mice downregulated Rgmc mRNA in tesponse to LPS
without differences in comparison to wiidtype mice indicates that II-6 is
flot required for the regulation of Rgmc mRNA in response to LPS. This
response contrast with hepcidin, which is regulated by Il-6 in vitro, and
has an impaired regulation in Il-6 knockout mice injected with LPS (107).
Since Tnf-Œ is capable of Rgmc mRNA regulation both in vitro and in
vivo, if is possible that this cytokine, which is produced after LPS
stimulation, may be implicated in the regulation cf Rgmc mRNA levels in
LPS treated mice. However, further studies using Tflf-Œ knockout mice
or antibody-mediated Tnf-a blocking in vivo will be required f0
understand whether that cytokine is essential for Rgmc mRNA
regulation in response to LPS or if other cytokines are also capable of
inhibiting Rgmc mRNA expression.
In conclusion, we show that mouse Rgmc has the same pattern of
expression as found in humans, being expressed in skeletal muscle,
heart and liver, of which the iast two are the main organs affected in JH.
In the liver, the Rgmc transcript was detected in the hepatocytes, and
was absent from macrophages and other liver mononuclear celis,
indicating that the contrai of Rgmc function in this organ is likely
mediated by hepatocytes.
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Hepatic Rgmc mRNA expression was regulated by systemic
inflammation and hypoxia, but flot by iron levels, disruption cf Hfe or
132m, or anemia.
We found that cardiac Rgmc ïs also regulated in inflammation and that
both hepatic and cardiac Rgmc are on the T1r4 pathway, similar to what
is was found for hepcidïn (102). However, Rgmc and hepcidin regulatory
pathways deviate and while Il-6 regulates hepcidin, Rgmc is regulated
by Tflf-Œ.
These findïngs provide important insights into the regulatory pathways
impacting iron metabolism changes that may be relevant te disease
settings affecting iron homeostasis.
Although it ïs important to elucidate how Rgmc transcription is regulated,
the physiologic relevance cf the identified changes found will benefit
from studies at the protein level. The recent commercialization cf anti
Rgmc antibodies wilI allow for additional studies concerning how the
transcriptional regulation 15 reflected at the protein level and how Rgmc
secretion is controlled.
Future perspectives
Iron is implicated in the regulation 0f Tnf-Œ by LPS since iron overloaded
mice have a higher Tflf-Œ response than contros as observed by US
(data flot shown). Additionally, as shown in this work, Tnf-a is implicated
in the regulatïon of iron homeostasis genes.
These observations suggest a cross-communication mechanism
between the inflammatory and iron regulatory pathways. Interestingly,
hypoxia may also be implicated in this cross-communication, since it
enhances the Tnf-Œ response to LPS (108).
We believe that this putative cross-communication participates in the
regulation of iron homeostasis through the reguation cf Tnf-Œ.
We hypothesize that Rgmc regulates hepcidin and other iron-related
genes in response to a cross talk between hypoxia, iron eveis and the
immune system through a Tnf-x-related pathway. To test this
hypothesis, we propose the foltowing experimentat strategies:
1. The activation of genes by T1r4 is mediated by two transcription
factors: Nf-icb and interferon regulatory factor (IRF)3 (109).
To investigate the role 0f these proteins in the differential regulation 0f
Rgmc and hepcidin by T1r4 we wiII study in vivo iron homeostasis during
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inflammation using knockout mice cf downstream targets of Tlr4. In
addition, we will investïgate how chemical inhibition and dominant
negative forms 0f the proteins on the Tlr4 pathway alter iron
homeostasis in vitro.
2. Heat shock protein (HSP)70 and nitric oxide (NO) are modulated in
response te the iron regulators: iron levels, hypoxia and inflammation
(110, 111) and are implicated in the modulation of Tnf-alpha production
(108, 112), filling our criteria for elements implicated in a cross-
communication between the iron regulators.
To explore the participation cf HSPZO and NO on Tnf-alpha secretion
and Rgmc regulation, we wiN study iron homeostasis in response te the
activation or inhibition of those factors in vivo and in vitro.
3. Rgmc seems to be capable cf mediating iron-sensing both as a
membrane-bound and as a secreted molecule (97). The over
expression cf the Rgmc receptor, neogenin is accompanied by an
increase in intracellular iron levels (96) and seems te give a growth
advantage te cancer cells (113).
Te explore the downstream pathway cf Rgmc through neogenin and its
relevance in cancer, we will investigate how neogenin is regulated in
response to the regulators cf iron homeostasis by qRT-PCR. In addition
we will use microchip analysis and 2D gel electrophoresis to identify
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neogenin downstream targets. Finally, we will investigate how neogenin
disruption affects growth and survival cf neoplasic cells.
Significance
Long periods of inflammation, such as found in chronic infections,
alcohol abuse, cancer and autoimmune diseases, causes a sustained
sequestration 0f itOfl in hepatocytes and macrophages, accompanied by
a strong inhibition cf iron absorption due to the high hepcidin levels. This
sequestration leads to both hyperferremia in hepatocytes and
macrophages, and serum hypoferremia. Insufficient hemoglobin
production derived from the hypoferremia ultimately leads to anemia cf
chronic disease (ACD).
In addition, the upregulation of neogenin in breast (113), esophageous
(114) and ovarian (Le Page et ai, unpublished data) cancers, which
tequire large amounts of iron for tumor growth, suggests that the
HJV/neogenin pathway may be targeted in cancer therapies to deprive
the neoplasic masses of iron.
The understanding cf the regulation cf the HJV pathway and its
downstream elements may provide targets for therapies aimed at
ameliorating the symptomatology cf ACD and reducing the availability cf
iron fer tumor growth as a cc-therapy in cancer treatment.
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